Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30951580 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL3168608 | 0.95 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL30100601 | 0.94 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL21902756 | 0.94 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL4872484 | 0.90 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL6483625 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL1034120 | 0.88 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AHPGDMAPT | |
| SCHEMBL6246974 | 0.86 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL3178525 | 0.86 | HPGD (0.53) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL340393 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9AHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | claimed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | claimed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | disclosed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |